Endometriosis-Pipeline Review, H1 2015

Endometriosis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6032IDB
  • |
  • Pages: 127
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Endometriosis-Pipeline Review, H1 2015


Global Markets Direct's, 'Endometriosis-Pipeline Review, H1 2015', provides an overview of the Endometriosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Endometriosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Endometriosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Endometriosis Overview 11

Therapeutics Development 12

Pipeline Products for Endometriosis-Overview 12

Pipeline Products for Endometriosis-Comparative Analysis 13

Endometriosis-Therapeutics under Development by Companies 14

Endometriosis-Therapeutics under Investigation by Universities/Institutes 17

Endometriosis-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Endometriosis-Products under Development by Companies 22

Endometriosis-Products under Investigation by Universities/Institutes 24

Endometriosis-Companies Involved in Therapeutics Development 25

AbbVie Inc. 25

Addex Therapeutics Ltd 26

APAvadis Biotechnologies Srl 27

Astellas Pharma Inc. 28

Bayer AG 29

Dongkook Pharmaceutical Co., Ltd. 30

ElexoPharm GmbH 31

EndoCeutics, Inc. 32

Euroscreen S.A. 33

Evotec AG 34

Forendo Pharma Oy 35

GlaxoSmithKline plc 36

Isifer AB 37

Kissei Pharmaceutical Co., Ltd. 38

Lipicard Technologies Limited 39

Neurocrine Biosciences, Inc. 40

Orphagen Pharmaceuticals, Inc. 41

Philogen S.p.A. 42

PregLem SA 43

Repros Therapeutics Inc. 44

SK Chemicals Co., Ltd. 45

Takeda Pharmaceutical Company Limited 46

ValiRx Plc 47

Endometriosis-Therapeutics Assessment 48

Assessment by Monotherapy Products 48

Assessment by Combination Products 49

Assessment by Target 50

Assessment by Mechanism of Action 52

Assessment by Route of Administration 54

Assessment by Molecule Type 56

Drug Profiles 58

(anastrozole + levonorgestrel)-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

acolbifene hydrochloride + GnRH agonist + prasterone-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

ADX-68692-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ASP-1707-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

BAY-1026153-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

BAY-1128688-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

bentamapimod-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Drug to Inhibit C-Jun for Endometriosis-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Drug to Target RERG for Endometriosis-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Drugs for Endometriosis-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Drugs for Endometriosis and Uterine Fibroids-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

elagolix sodium-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Endole-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

epelsiban besylate-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

ESN-364-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

EVE-104-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

F8IL-4-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

FP-5677-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

goserelin biosimilar-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

KLH-2109-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

LT-6121-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

NCE-403-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Peptides for Cancer and Endometriosis-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

PGL-2001-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

relugolix-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

SR-16234-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

telapristone acetate-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

triptorelin pamoate biosimilar-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

VAL-201-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

vilaprisan-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

VPE-001-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

Endometriosis-Recent Pipeline Updates 105

Endometriosis-Dormant Projects 118

Endometriosis-Discontinued Products 120

Endometriosis-Product Development Milestones 121

Featured News & Press Releases 121

Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201 121

Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples 121

Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201 121

Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis 122

Apr 25, 2013: ValiRx Receives Australian Patent For VAL201 123

Nov 13, 2012: Repros Presents Proellex Clinical Updates At Lazard Capital Markets 9th Annual Healthcare Conference 123

Oct 08, 2012: Repros Therapeutics's Proellex Receives FDA Acceptance For Reclassification Of Clinical Hold Status 123

Aug 27, 2012: FDA Provides Recommendations For Phase II Protocol For Repros' Proellex In Treatment Of Endometriosis 124

Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 125

Jul 16, 2012: FDA Provides Guidance To Repros For Conducting Phase II Study Of Proellex In Treatment Of Endometriosis 125

Appendix 126

Methodology 126

Coverage 126

Secondary Research 126

Primary Research 126

Expert Panel Validation 126

Contact Us 127

Disclaimer 127

List of Tables

Number of Products under Development for Endometriosis, H1 2015 12

Number of Products under Development for Endometriosis-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Comparative Analysis by Unknown Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Investigation by Universities/Institutes, H1 2015 24

Endometriosis-Pipeline by AbbVie Inc., H1 2015 25

Endometriosis-Pipeline by Addex Therapeutics Ltd, H1 2015 26

Endometriosis-Pipeline by APAvadis Biotechnologies Srl, H1 2015 27

Endometriosis-Pipeline by Astellas Pharma Inc., H1 2015 28

Endometriosis-Pipeline by Bayer AG, H1 2015 29

Endometriosis-Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 30

Endometriosis-Pipeline by ElexoPharm GmbH, H1 2015 31

Endometriosis-Pipeline by EndoCeutics, Inc., H1 2015 32

Endometriosis-Pipeline by Euroscreen S.A., H1 2015 33

Endometriosis-Pipeline by Evotec AG, H1 2015 34

Endometriosis-Pipeline by Forendo Pharma Oy, H1 2015 35

Endometriosis-Pipeline by GlaxoSmithKline plc, H1 2015 36

Endometriosis-Pipeline by Isifer AB, H1 2015 37

Endometriosis-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 38

Endometriosis-Pipeline by Lipicard Technologies Limited, H1 2015 39

Endometriosis-Pipeline by Neurocrine Biosciences, Inc., H1 2015 40

Endometriosis-Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 41

Endometriosis-Pipeline by Philogen S.p.A., H1 2015 42

Endometriosis-Pipeline by PregLem SA, H1 2015 43

Endometriosis-Pipeline by Repros Therapeutics Inc., H1 2015 44

Endometriosis-Pipeline by SK Chemicals Co., Ltd., H1 2015 45

Endometriosis-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 46

Endometriosis-Pipeline by ValiRx Plc, H1 2015 47

Assessment by Monotherapy Products, H1 2015 48

Assessment by Combination Products, H1 2015 49

Number of Products by Stage and Target, H1 2015 51

Number of Products by Stage and Mechanism of Action, H1 2015 53

Number of Products by Stage and Route of Administration, H1 2015 55

Number of Products by Stage and Molecule Type, H1 2015 57

Endometriosis Therapeutics-Recent Pipeline Updates, H1 2015 105

Endometriosis-Dormant Projects, H1 2015 118

Endometriosis-Dormant Projects (Contd..1), H1 2015 119

Endometriosis-Discontinued Products, H1 2015 120

List of Figures

Number of Products under Development for Endometriosis, H1 2015 12

Number of Products under Development for Endometriosis-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 48

Assessment by Combination Products, H1 2015 49

Number of Products by Top 10 Targets, H1 2015 50

Number of Products by Stage and Top 10 Targets, H1 2015 50

Number of Products by Top 10 Mechanism of Actions, H1 2015 52

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 52

Number of Products by Top 10 Routes of Administration, H1 2015 54

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 55

Number of Products by Top 10 Molecule Types, H1 2015 56

Number of Products by Stage and Top 10 Molecule Types, H1 2015 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

AbbVie Inc.

Addex Therapeutics Ltd

APAvadis Biotechnologies Srl

Astellas Pharma Inc.

Bayer AG

Dongkook Pharmaceutical Co., Ltd.

ElexoPharm GmbH

EndoCeutics, Inc.

Euroscreen S.A.

Evotec AG

Forendo Pharma Oy

GlaxoSmithKline plc

Isifer AB

Kissei Pharmaceutical Co., Ltd.

Lipicard Technologies Limited

Neurocrine Biosciences, Inc.

Orphagen Pharmaceuticals, Inc.

Philogen S.p.A.

PregLem SA

Repros Therapeutics Inc.

SK Chemicals Co., Ltd.

Takeda Pharmaceutical Company Limited

ValiRx Plc

Endometriosis Therapeutic Products under Development, Key Players in Endometriosis Therapeutics, Endometriosis Pipeline Overview, Endometriosis Pipeline, Endometriosis Pipeline Assessment

select a license
Single User License
USD 2000 INR 146960
Site License
USD 4000 INR 293920
Corporate User License
USD 6000 INR 440880



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com